# EDGAR Filing Document

**Accession Number:** 0000915913
**File Stem:** 0000915913-26-000016
**Filing Date:** 2026-2
**Character Count:** 57069
**Document Hash:** ea4e4f54e467391053da0e466b24a933
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000915913-26-000016.hdr.sgml**: 20260211

**ACCESSION NUMBER**: 0000915913-26-000016

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260211

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260211

**DATE AS OF CHANGE**: 20260211

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALBEMARLE CORP
- **CENTRAL INDEX KEY:** 0000915913
- **STANDARD INDUSTRIAL CLASSIFICATION:** PLASTICS, MATERIALS, SYNTH RESINS & NONVULCAN ELASTOMERS [2821]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 541692118
- **STATE OF INCORPORATION:** VA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12658
- **FILM NUMBER:** 26621057

**BUSINESS ADDRESS:**
- **STREET 1:** 4250 CONGRESS STREET
- **STREET 2:** SUITE 900
- **CITY:** CHARLOTTE
- **STATE:** NC
- **ZIP:** 28209
- **BUSINESS PHONE:** 980-299-5700

**MAIL ADDRESS:**
- **STREET 1:** 4250 CONGRESS STREET
- **STREET 2:** SUITE 900
- **CITY:** CHARLOTTE
- **STATE:** NC
- **ZIP:** 28209

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ECHEM INC
- **DATE OF NAME CHANGE:** 19931208

?xml version='1.0' encoding='ASCII'? alb-20260211

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

_________________________________

**FORM 8-K**

_________________________________

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported) February 11, 2026** 

_________________________________

**ALBEMARLE CORPORATION** 

**(Exact name of Registrant as specified in charter)**

_________________________________

---

| | | |
|:---|:---|:---|
| **Virginia** | **001-12658** | **54-1692118** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>file number)** | **(IRS employer<br>identification no.)** |

---

**4250 Congress Street, Suite 900** 

**Charlotte, North Carolina 28209** 

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code**

**(980) 299-5700** 

**Not applicable**

**(Former name or former address, if changed since last report)**

_________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a- 12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| **COMMON STOCK, $.01 Par Value** | **ALB** | **New York Stock Exchange** |
| **DEPOSITARY SHARES, each representing a 1/20th interest in a share of 7.25% Series A Mandatory Convertible Preferred Stock** | **ALB PR A** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Section 2 - Financial Information**

**Item 2.02.&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On February 11, 2026, Albemarle Corporation (the "Company") issued a press release reporting its results for the fourth quarter ended December 31, 2025. A copy of this release is being furnished as Exhibit 99.1 hereto and incorporated herein by reference. In addition, on February 12, 2026, the Company will hold a teleconference for analysts and media to discuss results for the fourth quarter and fiscal year ended December 31, 2025. The teleconference will be webcast on the Company's website at <u>www.albemarle.com</u>.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

**Section 9 - Financial Statements and Exhibits**

**Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d) *Exhibits.*

---

| | |
|:---|:---|
| Exhibit | |
| <u>Number</u> | <u>Exhibit</u> |
| 99.1 | <u>[Press release, dated](a4q25earningsreleaseex991.htm)[February 1](a4q25earningsreleaseex991.htm)[1](a4q25earningsreleaseex991.htm)[, 202](a4q25earningsreleaseex991.htm)[6](a4q25earningsreleaseex991.htm)[issued by the Company.](a4q25earningsreleaseex991.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 11, 2026

**ALBEMARLE CORPORATION**

---

| | |
|:---|:---|
| By: | /s/ Neal R. Sheorey |
|  | Neal R. Sheorey |
|  | Executive Vice President and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| **Contact:** | |
| invest@albemarle.com | 1.980.308.6194 |

---

![alb-mainxreg4xx100a.jpg](alb-mainxreg4xx100a.jpg)

**Albemarle Reports Fourth Quarter and Full Year 2025 Results**

CHARLOTTE, N.C. – Feb. 11, 2026 - Albemarle Corporation (NYSE: ALB), a global leader in providing essential elements for mobility, energy, connectivity and health, today announced its results for the fourth quarter and full year ended December 31, 2025.

**Fourth Quarter and Full Year 2025 Results and Highlights**

*(Unless otherwise stated, all percentage changes represent year-over-year comparisons)*

• Fourth quarter net sales of $1.4 billion, up 16%; volume up 12%, including gains in all segments led by Energy Storage (up 17%) and Ketjen (up 13%).

• Fourth quarter net loss of ($414) million, or ($3.87) per diluted share, includes tax-related items and the write-down of assets in relation to the expected Ketjen transaction value; adjusted diluted loss per share of ($0.53)<sup>(a)</sup>.

• Fourth quarter adjusted EBITDA<sup>(a)</sup> of $269 million, up 7%, led by Energy Storage (+25%) and Ketjen (+39%).

• Full year cash from operations of $1.3 billion, representing more than 100% operating cash flow conversion<sup>(b)</sup>, driven primarily by cost and productivity improvements, working capital management, and a customer pre-payment received in January 2025.

• Free cash flow of $692 million<sup>(a)</sup> reflects strong operating cash flow conversion and significantly lower capital expenditures of $590 million (down 65% year-over-year).

• Achieved approximately $450 million of cost and productivity improvements, exceeding the initial target of $300 to $400 million.

• Closed sale of 50% stake in the Eurecat joint venture for $123 million cash in January 2026; on track to close sale of controlling stake in Ketjen in Q1 2026.

• Introducing full-year 2026 outlook considerations, including ranges based on updated lithium market price scenarios:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ New scenarios highlight improved lithium market conditions and operational performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Full-year 2026 capital expenditures expected to be approximately flat year-over-year, reflecting consistent sustaining capital, Ketjen divestiture and targeted growth capital focused on productivity gains and resource development.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Meaningful free cash flow generation assuming recent higher lithium prices.

(a)&nbsp;&nbsp;&nbsp;&nbsp;See Non-GAAP Reconciliations for further details.

(b)&nbsp;&nbsp;&nbsp;&nbsp;Defined as Operating Cash Flow divided by Adj. EBITDA, which is a non-GAAP measure. See Non-GAAP Reconciliations for further details.

------

**Fourth Quarter 2025 Results**

---

| | | | | |
|:---|:---|:---|:---|:---|
| *In millions, except per share amounts* | **Q4 2025** | **Q4 2024** | **$ Change** | **% Change**<sup>(c)</sup> |
| Net sales | $1428.0 | $1231.7 | $196.3 | 15.9% |
| Net (loss) income attributable to Albemarle Corporation | $(414.2) | $75.3 | $(489.5) | NM |
| Adjusted EBITDA<sup>(a)</sup> | $268.7 | $250.7 | $18.0 | 7.2% |
| Diluted (loss) earnings per share attributable to common shareholders | $(3.87) | $0.29 | $(4.16) | NM |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-operating pension and OPEB items<sup>(a)</sup> | 0.15 | (0.07) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-recurring and other unusual items<sup>(a)</sup> | 3.19 | (1.31) |  |  |
| Adjusted diluted loss per share attributable to common shareholders<sup>(a)(b)</sup> | $(0.53) | $(1.09) | $0.56 | 51.4% |

---

(a)&nbsp;&nbsp;&nbsp;&nbsp;See Non-GAAP Reconciliations for further details.

(b)&nbsp;&nbsp;&nbsp;&nbsp;Totals may not add due to rounding.

(c)&nbsp;&nbsp;&nbsp;&nbsp;Certain percentage changes are considered not meaningful ("NM")

Net sales for the fourth quarter of 2025 were $1.4 billion compared to $1.2 billion for the prior-year quarter, an increase of 16%, driven primarily by higher volumes in Energy Storage (+17%) and Ketjen (+13%) and higher pricing in Energy Storage. Net loss attributable to Albemarle of $414 million increased year-over-year by $490 million primarily due to tax-related items and the write-down of assets in relation to the expected Ketjen transaction value. Excluding these one-time items, adjusted net loss improved year-over-year. Adjusted EBITDA of $269 million increased by $18 million from the prior-year quarter primarily due to higher pricing in Energy Storage and higher volumes in Ketjen.

The effective income tax rate for the fourth quarter of 2025 was (55.2)%, compared to 13.8% in the same period of 2024. On an adjusted basis, the effective income tax rates were 561.1% and 446.9% for the fourth quarters of 2025 and 2024, respectively, with the increase primarily due to recording a valuation allowance on the entirety of U.S. deferred tax assets in the fourth quarter of 2025, as well as changes in geographic income mix, including the impact of previously recorded valuation allowances in Australia and China.

**Energy Storage Results**

---

| | | | | |
|:---|:---|:---|:---|:---|
| *In millions* | **Q4 2025** | **Q4 2024** | **$ Change** | **% Change** |
| Net Sales | $759.1 | $616.8 | $142.2 | 23.1% |
| Adjusted EBITDA | $167.1 | $133.7 | $33.4 | 25.0% |

---

Energy Storage net sales for the fourth quarter of 2025 were $759 million, an increase of $142 million, or 23%, primarily due to higher volumes (+17%) and pricing (+6%). Adjusted EBITDA of $167 million increased $33 million, or 25%, primarily due to higher pricing and cost and productivity improvements.

Energy Storage adjusted EBITDA for the full year 2025 was $697 million, down 8% versus the year prior, as higher sales volumes and cost and productivity improvements mostly offset lower lithium market pricing.

**Specialties Results**

---

| | | | | |
|:---|:---|:---|:---|:---|
| *In millions* | **Q4 2025** | **Q4 2024** | **$ Change** | **% Change** |
| Net Sales | $348.9 | $332.9 | $16.0 | 4.8% |
| Adjusted EBITDA | $68.6 | $72.9 | $(4.3) | (5.9)% |

---

Specialties net sales for the fourth quarter of 2025 were $349 million, an increase of $16 million, or 5%, primarily due to higher volumes (+2%) and pricing (+1%). Adjusted EBITDA of $69 million decreased $4 million versus the year-ago quarter primarily due to margin compression in lithium specialties, down from 2024 highs.

Specialties adjusted EBITDA for the full year 2025 was $276 million, increasing 21% year-over-year, as higher volumes and cost and productivity improvements more than offset lower pricing.

------

**Ketjen Results**

---

| | | | | |
|:---|:---|:---|:---|:---|
| *In millions* | **Q4 2025** | **Q4 2024** | **$ Change** | **% Change** |
| Net Sales | $320.1 | $281.9 | $38.1 | 13.5% |
| Adjusted EBITDA | $49.7 | $35.8 | $13.9 | 38.8% |

---

Ketjen net sales for the fourth quarter of 2025 were $320 million, up 14% compared to the prior-year quarter primarily due to higher fluidized catalytic cracking (FCC) volumes and timing of Clean Fuels technology (CFT) sales. Adjusted EBITDA of $50 million increased $14 million, driven by favorable product mix and lower input costs.

Ketjen adjusted EBITDA for the full year 2025 was $150 million, an increase of 15%, primarily due to increased FCC volumes.

**2026 Outlook Considerations**

**Total Corporate Outlook Considerations**

The table below reflects expected outcomes for the total company based on recently observed lithium market price scenarios. Outlook ranges for each scenario are based on variation in sales volume and product mix. Energy Storage production volumes are expected to increase year-over-year. Sales volumes are expected to be approximately flat following inventory drawdowns that occurred in 2025. All three scenarios assume flat market pricing flowing through Energy Storage's current contract book which includes approximately 40% of salts volume on long-term agreements. Scenarios also assume that spodumene pricing averages 10% of the lithium carbonate equivalent (LCE) price, while other costs are assumed to be constant.

---

| | | | |
|:---|:---|:---|:---|
| | **Total Corporate FY 2026E <br>Including Energy Storage Scenarios** | **Total Corporate FY 2026E <br>Including Energy Storage Scenarios** | **Total Corporate FY 2026E <br>Including Energy Storage Scenarios** |
| Observed market price case<sup>(a)</sup> | FY 2025 avg. | Jan. 2026 avg. | 2021-2025 avg. |
| Average lithium market price ($/kg LCE)<sup>(a)</sup> | ~$10 | ~$20 | ~$30 |
| Net sales | $4.1 - $4.3 billion | $5.7 - $6.0 billion | $7.5 - $7.8 billion |
| Adjusted EBITDA<sup>(b)</sup> | $0.9 - $1.0 billion | $2.4 - $2.6 billion | $4.2 - $4.4 billion |

---

(a)&nbsp;&nbsp;&nbsp;&nbsp;Price represents blend of relevant market pricing including spot and regional indices for the periods referenced.

(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the company is unable to estimate significant non-recurring or unusual items without unreasonable effort. See "Additional information regarding Non-GAAP Measures" for more information.

**Energy Storage Market Price Scenarios**

---

| | | | |
|:---|:---|:---|:---|
| | **Energy Storage FY 2026E** | **Energy Storage FY 2026E** | **Energy Storage FY 2026E** |
| Observed market price case<sup>(a)</sup> | FY 2025 avg. | Jan. 2026 avg. | 2021-2025 avg. |
| Average lithium market price ($/kg LCE)<sup>(a)</sup> | ~$10 | ~$20 | ~$30 |
| Net sales | $2.5 - $2.6 billion | $4.0 - $4.2 billion | $5.9 - $6.1 billion |
| Adjusted EBITDA | $0.7 - $0.8 billion | $2.1 - $2.3 billion | $3.9 - $4.1 billion |
| Equity in net income of unconsolidated investments (net of tax)<sup>(b)</sup> | $0.2 - $0.3 billion | $0.6 - $0.7 billion | $1.0 - $1.1 billion |

---

(a)&nbsp;&nbsp;&nbsp;&nbsp;Price represents blend of relevant market pricing including spot and regional indices for the periods referenced.

(b)&nbsp;&nbsp;&nbsp;&nbsp;Included in adjusted EBITDA on a pre-tax basis.

**Specialties Outlook Considerations**

Specialties outlook reflects modest volume growth in key end markets led by semiconductor and pharmaceutical partially offset by expected softness in automotive, building and construction and oil and gas.

Net sales are expected to be flat to down and adjusted EBITDA is expected to be lower in 2026 compared to 2025 due, in part, to lithium specialties pricing, which has adjusted lower from the previous peak, and reduced demand for clear brine fluids due to weakness in oil and gas markets. Production volume in 2026 is expected to be impacted by a major flooding event that occurred at our Jordan Bromine Company (JBC) joint venture in January 2026. JBC has since returned to full operating rates.

------

---

| | |
|:---|:---|
| | **Segment FY 2026E** |
| Specialties net sales | $1.2 - $1.4 billion |
| Specialties adjusted EBITDA | $170 - $230 million |

---

**Other Corporate Outlook Considerations**

Following the sale of a controlling stake in Ketjen, which is expected to close in the first quarter of 2026, the refining catalyst business earnings will be classified as equity income and included in Corporate, as will the results of the retained Performance Catalyst Solutions (PCS) business. The EBITDA and equity income contributions from these are expected to be immaterial post transaction.

Albemarle expects its 2026 capital expenditures to be roughly flat compared to 2025, in the range of $550 million to $600 million.

---

| | |
|:---|:---|
| | **Other Corporate FY 2026E** |
| Capital expenditures | $550 - $600 million |
| Depreciation and amortization | $660 - $680 million |
| Adjusted effective tax rate<sup>(a)</sup> | (50%) - 30% |
| Corporate adjusted EBITDA (incl. FX, Ketjen equity income & PCS) | ($20) - $20 million |
| Interest and financing expenses | $150 - $170 million |
| Weighted-average common shares outstanding (diluted) | ~118 million |

---

(a)&nbsp;&nbsp;&nbsp;&nbsp;Adjusted effective tax rate dependent on lithium market prices and geographic income mix

**Cash Flow and Capital Deployment**

Cash from operations of $1.3 billion for the year ended December 31, 2025 increased $594 million compared to the prior-year period due to cost and productivity improvements, cash management actions, including inventory reductions, and a customer prepayment received in January. Capital expenditures of $590 million were in-line with the company's most recent outlook and decreased by $1.1 billion versus the prior-year period, reflecting the impact of decisions that stopped or slowed spending and the completion of capacity expansions in Energy Storage and Specialties.

**Balance Sheet and Liquidity**

As of December 31, 2025, Albemarle had estimated liquidity of approximately $3.2 billion, including $1.6 billion of cash and equivalents, $1.5 billion available under its revolver and $105 million available on other credit lines. Total debt was $3.2 billion, representing a net debt to adjusted EBITDA ratio (as defined in our credit agreement) of approximately 2.0 times.

**Earnings Call**

---

| | |
|:---|:---|
| Date: | Thurs., Feb. 12, 2026 |
| Time: | 8:00 AM Eastern time |
| Dial-in (U.S.): | +1 800-590-8290 |
| Dial-in (International): | +1 240-690-8800 |
| Passcode: | ALBQ4 |

---

The company's earnings presentation and supporting material are available on Albemarle's website at https://investors.albemarle.com.

**About Albemarle**

Albemarle Corporation (NYSE: ALB) leads the world in transforming essential resources into critical ingredients for mobility, energy, connectivity, and health. We partner to pioneer new ways to move, power, connect and protect with people and planet in mind. A reliable and high-quality global supply of lithium and bromine allow us to deliver advanced solutions for our customers. Learn more about how the people of Albemarle are enabling a more resilient world at Albemarle.com, LinkedIn and X.

Albemarle regularly posts information to Albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, Securities and Exchange

------

Commission ("SEC") filings and other information regarding the company, its businesses and the markets it serves.

**Forward-Looking Statements**

This press release contains statements concerning our expectations, anticipations and beliefs regarding the future, which constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties, often contain words such as "ambition," "anticipate," "believe," "estimate," "expect," "goal," "guidance," "intend," "may," "outlook," "scenario," "should," "would," and "will". Forward-looking statements may include statements regarding: our 2026 company and segment outlooks, including expected market pricing of lithium carbonate equivalent and spodumene and other underlying assumptions and outlook considerations; planned sale of a controlling stake in Ketjen and the amount of the proceeds for the controlling stake in Ketjen and our interest in the Eurecat JV; timing for completion of both transactions, including obtaining regulatory approvals and meeting other closing conditions; expectations regarding use of proceeds from the both transactions; expected capital expenditure amounts and the corresponding impact on cash flow; expected impact of tariffs and other trade restrictions; plans and expectations regarding other projects and activities, cost reductions and accounting charges, and all other information relating to matters that are not historical facts. Factors that could cause Albemarle's actual results to differ materially from the outlook expressed or implied in any forward-looking statement include: changes in economic and business conditions; changes in trade policies and tariffs; financial and operating performance of customers; timing and magnitude of customer orders; fluctuations in lithium and spodumene market prices; production volume shortfalls; increased competition; changes in product demand; availability and cost of raw materials and energy; technological change and development; fluctuations in foreign currencies; changes in laws and government regulation; regulatory actions, proceedings, claims or litigation; cyber-security breaches, terrorist attacks, industrial accidents or natural disasters; risks related to the integration of artificial intelligence technologies into our operations; geopolitical conflicts and political unrest; our ability to retain key personnel and attract new skilled personnel; changes in inflation or interest rates; volatility in the debt and equity markets; acquisition and divestiture transactions; timing and success of projects; performance of Albemarle's partners in joint ventures and other projects; changes in credit ratings; and the other factors detailed from time to time in the reports Albemarle files with the SEC, including those described under "Risk Factors" in Albemarle's most recent Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q, which are filed with the SEC and available on the investor section of Albemarle's website (investors.albemarle.com) and on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date of this press release. Albemarle assumes no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

------

Albemarle Corporation and Subsidiaries

Consolidated Statements of (Loss) Income

(In Thousands Except Per Share Amounts) (Unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** |
| | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net sales | $1428031 | $1231713 | $5142733 | $5377526 |
| Cost of goods sold | 1230097 | 1093500 | 4474014 | 5314987 |
| Gross profit | 197934 | 138213 | 668719 | 62539 |
| Selling, general and administrative expenses | 155500 | 135996 | 550036 | 618048 |
| Goodwill impairment charges |  |  | 181070 |  |
| Long-lived asset impairment charges | 245600 |  | 245600 |  |
| Restructuring charges and asset write-offs | 2039 | (22206) | 7699 | 1134316 |
| Research and development expenses | 12181 | 20021 | 51398 | 86720 |
| Operating (loss) profit | (217386) | 4402 | (367084) | (1776545) |
| Interest and financing expenses | (57776) | (44703) | (207651) | (165619) |
| Other (expenses) income, net | (9828) | 117028 | 22662 | 178339 |
| (Loss) income before income taxes and equity in net income of unconsolidated investments | (284990) | 76727 | (552073) | (1763825) |
| Income tax expense | 157330 | 10613 | 156881 | 87085 |
| (Loss) income before equity in net income of unconsolidated investments | (442320) | 66114 | (708954) | (1850910) |
| Equity in net income of unconsolidated investments (net of tax) | 40560 | 18997 | 243744 | 715433 |
| Net (loss) income | (401760) | 85111 | (465210) | (1135477) |
| Net income attributable to noncontrolling interests | (12419) | (9818) | (45418) | (43972) |
| Net (loss) income attributable to Albemarle Corporation | (414179) | 75293 | (510628) | (1179449) |
| Mandatory convertible preferred stock dividends | (41687) | (41688) | (166750) | (136647) |
| Net (loss) income attributable to Albemarle Corporation common shareholders | $(455866) | $33605 | $(677378) | $(1316096) |
| Basic (loss) earnings per share attributable to common shareholders | $(3.87) | $0.29 | $(5.76) | $(11.20) |
| Diluted (loss) earnings per share attributable to common shareholders | $(3.87) | $0.29 | $(5.76) | $(11.20) |
| Weighted-average common shares outstanding – basic | 117701 | 117549 | 117664 | 117516 |
| Weighted-average common shares outstanding – diluted | 117701 | 117723 | 117664 | 117516 |

---

------

Albemarle Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

(In Thousands) (Unaudited)

---

| | | |
|:---|:---|:---|
| | **December 31,**<br>**2025** | **December 31,**<br>**2024** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $1618001 | $1192230 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade accounts receivable | 593502 | 742201 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other accounts receivable | 105110 | 238384 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 1179271 | 1502531 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 140440 | 166916 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current assets held for sale | 371815 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 4008139 | 3842262 |
| Property, plant and equipment, at cost | 11768840 | 12523368 |
| Less accumulated depreciation and amortization | 3156429 | 3191898 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net property, plant and equipment | 8612411 | 9331470 |
| Investments | 900926 | 1117739 |
| Other assets | 647185 | 504711 |
| Goodwill | 1499657 | 1582714 |
| Other intangibles, net of amortization | 214233 | 230753 |
| Noncurrent assets held for sale | 491660 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $16374211 | $16609649 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable to third parties | $779160 | $793455 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable to related parties | 134369 | 150432 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 521831 | 467997 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt | 74077 | 398023 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends payable | 61387 | 61282 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 35467 | 95275 |
| Current liabilities held for sale | 191753 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 1798044 | 1966464 |
| Long-term debt | 3119464 | 3118142 |
| Postretirement benefits | 44744 | 31930 |
| Pension benefits | 117361 | 116192 |
| Other noncurrent liabilities | 1084892 | 819204 |
| Deferred income taxes | 368275 | 358029 |
| Noncurrent liabilities held for sale | 59970 |  |
| Commitments and contingencies |  |  |
| Equity: |  |  |
| Albemarle Corporation shareholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock | 1178 | 1176 |
| &nbsp;&nbsp;&nbsp;&nbsp;Mandatory convertible preferred stock | 2235105 | 2235105 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in-capital | 3018213 | 2985606 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (334807) | (742062) |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 4613676 | 5481692 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Albemarle Corporation shareholders' equity | 9533365 | 9961517 |
| Noncontrolling interests | 248096 | 238171 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total equity | 9781461 | 10199688 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $16374211 | $16609649 |

---

------

Albemarle Corporation and Subsidiaries

Selected Consolidated Cash Flow Data

(In Thousands) (Unaudited)

---

| | | |
|:---|:---|:---|
| | **Year Ended** | **Year Ended** |
| | **December 31,** | **December 31,** |
| | **2025** | **2024** |
| Cash and cash equivalents at beginning of year | $1192230 | $889900 |
| Cash flows from operating activities: |  |  |
| Net loss | (465210) | (1135477) |
| Adjustments to reconcile net loss to cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 658678 | 588638 |
| &nbsp;&nbsp;&nbsp;Non-cash goodwill impairment charges | 181070 |  |
| &nbsp;&nbsp;&nbsp;Non-cash long-lived asset impairment charges | 245600 |  |
| &nbsp;&nbsp;&nbsp;Non-cash restructuring and asset write-offs |  | 1013444 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation and other | 40271 | 32141 |
| &nbsp;&nbsp;&nbsp;Equity in net income of unconsolidated investments (net of tax) | (243744) | (715433) |
| &nbsp;&nbsp;&nbsp;Dividends received from unconsolidated investments and nonmarketable securities | 93739 | 358933 |
| &nbsp;&nbsp;&nbsp;Pension and postretirement expense (benefit) | 23377 | (5274) |
| &nbsp;&nbsp;&nbsp;Pension and postretirement contributions | (20441) | (19379) |
| &nbsp;&nbsp;&nbsp;Realized loss on investments in marketable securities |  | 33746 |
| &nbsp;&nbsp;&nbsp;Unrealized (gain) loss on investments in marketable securities | (14088) | 30073 |
| &nbsp;&nbsp;&nbsp;Loss on early extinguishment of debt | 7471 |  |
| &nbsp;&nbsp;&nbsp;Deferred income taxes | 81169 | (230406) |
| &nbsp;&nbsp;&nbsp;Changes in current assets and liabilities, net of effects of acquisitions and divestitures: |  |  |
| &nbsp;&nbsp;&nbsp;Decrease in accounts receivable | 47315 | 555218 |
| &nbsp;&nbsp;&nbsp;Decrease in inventories | 212351 | 1055036 |
| &nbsp;&nbsp;&nbsp;Decrease in other current assets | 4027 | 244987 |
| &nbsp;&nbsp;&nbsp;Increase (decrease) in accounts payable to third parties | 144208 | (462839) |
| &nbsp;&nbsp;&nbsp;(Decrease) in accounts payable to related parties | (16063) | (399398) |
| &nbsp;&nbsp;&nbsp;(Decrease) in accrued expenses and income taxes payable | (36753) | (140099) |
| &nbsp;&nbsp;&nbsp;Noncurrent liability changes and other, net | 339290 | (116035) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 1282267 | 687876 |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Capital expenditures | (589801) | (1680529) |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of property and equipment | 32812 | 29102 |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of investments | 290908 |  |
| &nbsp;&nbsp;&nbsp;Proceeds (payments) from settlement of foreign currency forward contracts, net | 114236 | (15595) |
| &nbsp;&nbsp;&nbsp;Sales of marketable securities, net | 6077 | 82520 |
| &nbsp;&nbsp;&nbsp;Investments in equity investments and nonmarketable securities | (239) | (270) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (146007) | (1584772) |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of mandatory convertible preferred stock |  | 2236750 |
| &nbsp;&nbsp;&nbsp;Proceeds from borrowings of long-term debt and credit agreements | 56728 | 112439 |
| &nbsp;&nbsp;&nbsp;Repayments of long-term debt and credit agreements | (505736) | (112439) |
| &nbsp;&nbsp;&nbsp;Other repayments, net | (5657) | (631834) |
| &nbsp;&nbsp;&nbsp;Dividends paid to common shareholders | (190530) | (188530) |
| &nbsp;&nbsp;&nbsp;Dividends paid to mandatory convertible preferred shareholders | (166750) | (122746) |
| &nbsp;&nbsp;&nbsp;Dividends paid to noncontrolling interests | (18169) | (37194) |
| &nbsp;&nbsp;&nbsp;Proceeds from exercise of stock options | 3240 | 374 |
| &nbsp;&nbsp;&nbsp;Withholding taxes paid on stock-based compensation award distributions | (7258) | (11891) |
| &nbsp;&nbsp;&nbsp;Other | (55) | (3194) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by financing activities | (834187) | 1241735 |
| Net effect of foreign exchange on cash and cash equivalents | 123698 | (42509) |
| Increase in cash and cash equivalents | 425771 | 302330 |
| Cash and cash equivalents at end of period | $1618001 | $1192230 |

---

------

Albemarle Corporation and Subsidiaries

Consolidated Summary of Segment Results

(In Thousands) (Unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** |
| | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Net sales:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Energy Storage | $759059 | $616822 | $2710035 | $3015121 |
| &nbsp;&nbsp;&nbsp;Specialties | 348901 | 332942 | 1366435 | 1325983 |
| &nbsp;&nbsp;&nbsp;Ketjen | 320071 | 281949 | 1066263 | 1036422 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total net sales | $1428031 | $1231713 | $5142733 | $5377526 |
| **Adjusted EBITDA:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Energy Storage | $167058 | $133678 | $697215 | $757540 |
| &nbsp;&nbsp;&nbsp;Specialties | 68552 | 72875 | 275739 | 228504 |
| &nbsp;&nbsp;&nbsp;Ketjen | 49677 | 35778 | 150398 | 131066 |
| &nbsp;&nbsp;&nbsp; Total segment adjusted EBITDA | 285287 | 242331 | 1123352 | 1117110 |
| &nbsp;&nbsp;&nbsp;Corporate | (16543) | 8353 | (25359) | 22668 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total adjusted EBITDA | $268744 | $250684 | $1097993 | $1139778 |

---

See accompanying non-GAAP reconciliations below.

**Additional Information regarding Non-GAAP Measures**

It should be noted that adjusted net (loss) income attributable to Albemarle Corporation, adjusted net loss attributable to Albemarle Corporation common shareholders, adjusted diluted loss per share attributable to common shareholders, non-operating pension and other post-employment benefit ("OPEB") items per diluted share, non-recurring and other unusual items per diluted share, adjusted effective income tax rates, EBITDA, adjusted EBITDA (on a consolidated basis), EBITDA margin and adjusted EBITDA margin, operating cash flow conversion, and free cash flow are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States, or GAAP. These non-GAAP measures should not be considered as alternatives to Net (loss) income attributable to Albemarle Corporation ("earnings") or other comparable measures calculated and reported in accordance with GAAP. These measures are presented here to provide additional useful measurements to review the company's operations, provide transparency to investors and enable period-to-period comparability of financial performance. The company's chief operating decision maker uses these measures to assess the ongoing performance of the company and its segments, as well as for business and enterprise planning purposes.

A description of other non-GAAP financial measures that Albemarle uses to evaluate its operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP can be found on the following pages of this press release, which is also available on Albemarle's website at https://investors.albemarle.com. The company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the company is unable to estimate significant non-recurring or unusual items without unreasonable effort. The amounts and timing of these items are uncertain and could be material to the company's results calculated in accordance with GAAP.

------

**ALBEMARLE CORPORATION AND SUBSIDIARIES**

**Non-GAAP Reconciliations**

**(Unaudited)**

See below for a reconciliation of adjusted net (loss) income attributable to Albemarle Corporation, adjusted net loss attributable to Albemarle Corporation common shareholders, EBITDA and adjusted EBITDA (on a consolidated basis), which are non-GAAP financial measures, to Net (loss) income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reported in accordance with GAAP. Adjusted net loss attributable to Albemarle Corporation is defined as net loss attributable to Albemarle Corporation before the non-recurring, other unusual and non-operating pension and other post-employment benefit (OPEB) items as listed below. The non-recurring and unusual items may include acquisition and integration related costs, gains or losses on sales of businesses, restructuring charges, facility divestiture charges, certain litigation and arbitration costs and charges, and other significant non-recurring items. Adjusted net loss attributable to Albemarle Corporation common stockholders is defined as adjusted net loss attributable to Albemarle Corporation after mandatory convertible preferred stock dividends. EBITDA is defined as net (loss) income attributable to Albemarle Corporation before interest and financing expenses, income tax expense, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA plus or minus the proportionate share of Windfield Holdings income tax expense, non-recurring, other unusual and non-operating pension and OPEB items as listed below.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** |
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| <u>In thousands, except percentages and per share amounts</u> | $**% of net sales** | $**% of net sales** | $**% of net sales** | $**% of net sales** |
| Net (loss) income attributable to Albemarle Corporation |  |  |  |  |
| Add back: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-operating pension and OPEB items (net of tax) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-recurring and other unusual items (net of tax) |  |  |  |  |
| Adjusted net (loss) income attributable to Albemarle Corporation |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Mandatory convertible preferred stock dividends |  |  |  |  |
| Adjusted net loss attributable to Albemarle Corporation common shareholders |  |  |  |  |
| Adjusted diluted loss per share attributable to common shareholders |  |  |  |  |
| Adjusted weighted-average common shares outstanding – diluted |  |  |  |  |
| Net (loss) income attributable to Albemarle Corporation | (29.0)% | 6.1% | (9.9)% | (21.9)% |
| Add back: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest and financing expenses | 4.0% | 3.6% | 4.0% | 3.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 11.0% | 0.9% | 3.1% | 1.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 11.5% | 13.2% | 12.8% | 10.9% |
| EBITDA | (2.5)% | 23.8% | 10.0% | (6.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Proportionate share of Windfield income tax expense | 1.1% | 0.5% | 1.8% | 5.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-operating pension and OPEB items | 1.2% | (0.8)% | 0.3% | (0.2)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-recurring and other unusual items | 19.0% | (3.2)% | 9.2% | 22.1% |
| Adjusted EBITDA | 18.8% | 20.4% | 21.4% | 21.2% |
| Net sales |  |  |  |  |

---

Non-operating pension and OPEB items, consisting of mark-to-market actuarial gains/losses, settlements/curtailments, interest cost and expected return on assets, are not allocated to Albemarle's operating segments and are included in the Corporate category. In addition, the company believes that these components of pension cost are mainly driven by market performance, and the company manages these separately from the operational performance of the company's businesses. In accordance with GAAP, these non-operating pension and OPEB items are included in Other (expenses) income, net. Non-operating pension and OPEB items were as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** |
| | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;MTM actuarial loss (gain) | $17246 | $(9831) | $17246 | $(9831) |
| &nbsp;&nbsp;&nbsp;Interest cost | 8717 | 8696 | 35427 | 34225 |
| &nbsp;&nbsp;&nbsp;Expected return on assets | (9231) | (9207) | (34963) | (35729) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $16732 | $(10342) | $17710 | $(11335) |

---

------

In addition to the non-operating pension and OPEB items disclosed above, the company has identified certain other items and excluded them from Albemarle's adjusted net (loss) income calculation for the periods presented. A listing of these items, as well as a detailed description of each follows below (per diluted share):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Year Ended** | **Year Ended** |
| | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| Restructuring charges and asset write-offs<sup>(1)</sup> | $0.02 | $(0.21) | $0.04 | $9.77 |
| Goodwill impairment charges<sup>(2)</sup> | 0.04 |  | 1.54 |  |
| Long-lived asset impairment charges<sup>(3)</sup> | 2.09 |  | 2.09 |  |
| Acquisition and integration related costs<sup>(4)</sup> | 0.04 | 0.01 | 0.07 | 0.04 |
| (Gain) loss in fair value of public equity securities<sup>(5)</sup> | (0.07) | 0.03 | (0.09) | 0.53 |
| Loss on extinguishment of debt<sup>(6)</sup> | 0.06 |  | 0.06 |  |
| Other<sup>(7)</sup> | 0.28 | (0.19) | 0.35 | (0.42) |
| Tax related items<sup>(8)</sup> | 0.73 | (0.95) | 0.75 | (1.00) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total non-recurring and other unusual items | $3.19 | $(1.31) | $4.81 | $8.92 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Company took several actions during 2024 as part of a broader effort that are focused on preserving its world-class resource advantages, optimizing its global conversion network, improving the Company's cost competitiveness and efficiency, reducing capital intensity and enhancing the Company's financial flexibility. Those actions included stopping construction of Kemerton Trains 3 and 4, as well as certain other capital projects, placing Kemerton Train 2 in care and maintenance and transitioning the Company's operating structure to a fully integrated functional model (excluding Ketjen). Additionally, as part of this restructuring plan, we placed the Chengdu, China conversion plant into care and maintenance during the first half of 2025. As a result, the Company recorded restructuring and asset write-off charges of $2.0 million and $7.7 million in Restructuring charges and asset write-offs for the three months and year ended December 31, 2025, respectively, and a loss of $0.1 million and $0.2 million in Other (expenses) income, net for the three months and year ended December 31, 2025, respectively. Due to the impact of the valuation allowances, this resulted in total after-tax gains of $2.2 million and $5.2 million, or $0.02 and $0.04 per share for the three months and year ended December 31, 2025, respectively. The Company recorded restructuring and asset write-off charges (gains) of $3.8 million in Cost of goods sold during the three months and year ended December 31, 2024, and ($22.2) million and net charges of $1.2 billion during the three months and year ended December 31, 2024, respectively in Restructuring charges and asset write-offs. In addition, losses of $4.6 million and $26.1 million were recorded in Other (expenses) income, net for the three months and year ended December 31, 2024, respectively, related to these actions. In total, this resulted in after-tax (gains) losses of ($24.9) million and $1.1 billion, or ($0.21) and $9.77 per share for the three months and year ended December 31, 2024, respectively. The tax impact includes a valuation allowance to reverse the tax benefits associated with the expenses recorded in Australia.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Non-cash goodwill impairment charge of $181.1 million ($181.1 million or $1.54 per share after income tax expense) recorded during the year ended December 31, 2025 related to our Refining Solutions business within our Ketjen reportable segment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Non-cash long-lived asset impairment charge of $245.6 million ($245.6 million or $2.09 per share after income tax expense) recorded during the three months and year ended December 31, 2025 to reduce the carrying value of our Refining Solutions business to its fair value less costs to sell following classification as held for sale.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Costs related to the acquisition, integration and divestitures for various significant projects, recorded in Selling, general and administrative expenses for the three months and year ended December 31, 2025 were $3.2 million and $8.3 million ($4.3 million and $8.3 million after income taxes due to the impact of valuation allowances, or $0.04 and $0.07 per share), respectively, and for the three months and year ended December 31, 2024 were $2.3 million and $6.2 million ($1.8 million and $4.9 million after income taxes, or $0.01 and $0.04 per share), respectively.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)Gains of $8.0 million and $11.1 million ($8.7 million and $11.1 million after income taxes due to the impact of valuation allowances, or $0.07 and $0.09 per share) recorded in Other (expenses) income, net resulting from the net change in fair value of investments in public equity securities for the three months and year ended December 31, 2025, respectively. Losses of $4.8 million and $37.0 million recorded in Other (expenses) income, net resulting from the net change in fair value of investments in public equity securities for the three months and year ended December 31, 2024, respectively, and a loss of $33.7 million recorded in Other (expenses) income, net for the year ended December 31, 2024 resulting from the sale of investments in public equity securities ($3.7 million and $62.7 million after income taxes, or $0.03 and $0.53 per share).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)Included in Interest and financing expenses for the three months and year ended December 31, 2025 is a loss on early extinguishment of debt of $7.5 million ($0.06 per share, with no adjustment from income taxes due to the impact of valuation allowances), representing the unamortized discounts from the amendment of other debt.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)Other adjustments for the three months ended December 31, 2025 included amounts recorded in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cost of goods sold - $4.8 million related to the write-off of assets damaged in a severe weather incident in Jordan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Selling, general and administrative expenses - $9.2 million related to the write-off of assets damaged in a severe weather incident in Jordan and $0.8 million related to the write-off of certain fixed assets, partially offset by a $0.7 million gain resulting from the adjustment of severance expenses not related to a restructuring plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other (expenses) income, net - $14.3 million loss related to the sale of our ownership interest in the Nippon Aluminum Alkyls joint venture.

After income taxes, these net losses totaled $33.1 million, or $0.28 per share.

Other adjustments for the year ended December 31, 2025 included amounts recorded in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cost of goods sold - $4.8 million related to the write-off of assets damaged in a severe weather incident in Jordan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Selling, general and administrative expenses - $9.2 million related to the write-off of assets damaged in a severe weather incident in Jordan, $3.1 million of severance expenses not related to a restructuring plan, $2.2 million related to the write-off of certain fixed assets, $2.0 million of expenses related to certain historical legal matters and $1.4 million of expenses related to the redemption of preferred equity in a Grace subsidiary, partially offset by $13.3 million of gains from the sale of assets not part of our production operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other (expenses) income, net - $38.0 million loss resulting from the redemption of preferred equity in a Grace subsidiary, $14.3 million loss related to the sale of our ownership interest in the Nippon Aluminum Alkyls joint venture and $1.9 million of charges for asset retirement obligations at a site not part of our operations, partially offset by $19.8 million of income from PIK dividends of the preferred equity in a Grace subsidiary prior to redemption and a $2.4 million gain primarily resulting from the adjustment of indemnification related to previously disposed businesses.

After income taxes, these net losses totaled $41.5 million, or $0.35 per share.

Other adjustments for the three months ended December 31, 2024 included amounts recorded in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other (expenses) income, net - $23.5 million of gains from the sale of assets at a site not part of our operations, $9.5 million of income from PIK dividends of preferred equity in a Grace subsidiary, a $1.4 million net gain primarily resulting from the adjustment of indemnification related to previously disposed businesses, partially offset by $2.1 million of a loss related to the fair value adjustment of a nonmarketable security investment.

After income taxes, these net gains totaled $22.7 million, or $0.19 per share.

Other adjustments for the year ended December 31, 2024 included amounts recorded in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cost of goods sold - $1.4 million of expenses related to non-routine labor and compensation related costs that are outside normal compensation arrangements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Selling, general and administrative - $5.3 million of expenses related to certain historical legal and environmental matters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other (expenses) income, net - $40.9 million of gains from the sale of assets at sites not part of our operations, $36.3 million of income from PIK dividends of preferred equity in a Grace subsidiary, a $1.8 million net gain primarily resulting from the adjustment of indemnification related to previously disposed businesses and a $0.6 million gain from an updated cost estimate

------

of an environmental reserve at a site not part of our operations, partially offset by $2.9 million of charges for asset retirement obligations at a site not part of our operations and $2.1 million of a loss related to the fair value adjustment of a nonmarketable security investment.

After income taxes, these net gains totaled $49.0 million, or $0.42 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8)&nbsp;&nbsp;&nbsp;&nbsp;Included in Income tax expense for the three months and year ended December 31, 2025 are discrete net tax expenses of $86.2 million, or $0.73 per share, and $88.1 million, or $0.75 per share, respectively, primarily related to a U.S. basis difference in Ketjen entities.

&nbsp;&nbsp;&nbsp;&nbsp;Included in Income tax expense for the three months and year ended December 31, 2024 are discrete net tax benefits of $111.4 million, or $0.95 per share, and $117.5 million, or $1.00 per share, respectively, primarily related to the impact of valuation allowances on a return to provision, partially offset by the increase in a foreign tax reserve.

See below for a reconciliation of the adjusted effective income tax rate, the non-GAAP financial measure, to the effective income tax rate, the most directly comparable financial measure calculated and reporting in accordance with GAAP (in thousands, except percentages).

---

| | | | |
|:---|:---|:---|:---|
| | **(Loss) income before income taxes and equity in net income of unconsolidated investments** | **Income tax expense (benefit)** | **Effective income tax rate** |
| **Three months ended December 31, 2025:** | | | |
| As reported | $(284990) | $157330 | (55.2)% |
| Non-recurring, other unusual and non-operating pension and OPEB items | 295527 | (98208) |  |
| As adjusted | $10537 | $59122 | 561.1% |
| **Three months ended December 31, 2024:** |  |  |  |
| As reported | $76727 | $10613 | 13.8% |
| Non-recurring, other unusual and non-operating pension and OPEB items | (49232) | 112272 |  |
| As adjusted | $27495 | $122885 | 446.9% |
| **Year ended December 31, 2025:** |  |  |  |
| As reported | $(552073) | $156881 | (28.4)% |
| Non-recurring, other unusual and non-operating pension and OPEB items | 498332 | (86419) |  |
| As adjusted | $(53741) | $70462 | (131.1)% |
| **Year ended December 31, 2024:** |  |  |  |
| As reported | $(1763825) | $87085 | (4.9)% |
| Non-recurring, other unusual and non-operating pension and OPEB items | 1178692 | 137914 |  |
| As adjusted | $(585133) | $224999 | (38.5)% |

---

See below for the calculation of operating cash flow conversion and a reconciliation of free cash flow, a non-GAAP measure, to net cash provided by operating activities, the most directly comparable financial measure calculated and reporting in accordance with GAAP. The Company defines as Net cash provided by operating activities from the statement of cash flows divided by adjusted EBITDA, which is a non-GAAP measure. A reconciliation of adjusted EBITDA, the non-GAAP financial measure, from net income (loss) attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reporting in accordance with GAAP, is provided in the above tables (in thousands, except percentages).

------

---

| | |
|:---|:---|
| | **Year Ended**<br>**December 31, 2025** |
| **Free cash flow:** | |
| Net cash provided by operating activities | $1282267 |
| Less: Capital expenditures | (589801) |
| &nbsp;&nbsp;Free cash flow | $692466 |
| **Operating cash flow conversion:** |  |
| Net cash provided by operating activities | $1282267 |
| Adjusted EBITDA | $1097993 |
| &nbsp;&nbsp;Operating cash flow conversion | 117% |

---

<br>